GlassScriptPhysician profile
Majed Alomar
NPI 1457960031
$1,378.88
in general payments reported to CMS, 2019-2025
18 companies · $58.93 in 2025
The $58.93 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $104 · 2022: $387 · 2023: $516 · 2024: $313 · 2025: $58.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $887.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $266.46 | 2022-2024 | Mavenclad |
| Ucb, INC. | $223.12 | 2023-2024 | Briviact |
| Novartis Pharmaceuticals Corporation | $184.76 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.21 | 2022-2023 | |
| Genentech USA, INC. | $83.29 | 2022-2023 | Ocrevus, Enspryng |
| Jazz Pharmaceuticals INC. | $77.71 | 2023-2024 | Epidiolex |
| Alexion Pharmaceuticals, INC. | $62.01 | 2021-2022 | |
| Pfizer INC. | $58.93 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $58.60 | 2022 | |
| Genzyme Corporation | $56.30 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $46.29 | 2021 | |
| Horizon Therapeutics Plc | $44.07 | 2022 | |
| Abbvie INC. | $29.78 | 2023 | Botox |
| Averitas Pharma INC. | $21.59 | 2023 | Qutenza |
| Eisai INC. | $19.23 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $17.37 | 2022 | |
| Amylyx Pharmaceuticals, INC. | $16.90 | 2024 | Relyvrio |
| Astrazeneca Pharmaceuticals LP | $16.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Majed Alomar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.